Tauvid™：首款获美国食品药品监督管理局批准用于阿尔茨海默病中tau蛋白病理成像的正电子发射断层显像（PET）示踪剂。
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease.
作者信息
Jie Caitlin V M L, Treyer Valerie, Schibli Roger, Mu Linjing
机构信息
Center for Radiopharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, 8093 Zurich, Switzerland.
Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland.
出版信息
Pharmaceuticals (Basel). 2021 Jan 30;14(2):110. doi: 10.3390/ph14020110.
Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer's disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.
Tauvid于2020年获得美国食品药品监督管理局（FDA）批准，用于基于tau病理对正在接受阿尔茨海默病（AD）评估的认知障碍成年患者进行正电子发射断层扫描（PET）成像。tau蛋白的异常聚集是AD中存在的主要病理之一，作为诊断和治疗靶点正受到越来越多的关注。在本综述中，我们总结了Tauvid的生产和质量控制、其临床应用、药理学和药代动力学，以及由于脱靶结合导致的局限性。此外，还简要概述了第二代Tau PET示踪剂。Tauvid的获批标志着AD研究领域向前迈进了一步，并为第二代tau示踪剂在临床上推进tau PET成像创造了机会。
Zotero 插件